 |
|
 |
|
 |
|
 |
|
 |
|
| What's New |
Center for Laser Surgery selected as clinical site for Reloxin Botulinum Toxin clinical trialThe Center for Laser Surgery is one of 20 sites worldwide involved in the open label Phase III clinical of an new Botulinum type A neurotoxin for the treatment of facial lines. This 12-month, 1200-patient study will examine safety and efficacy of this new Botulinum complex in the treatment of facial expression lines
|
